that uterine bleeding due to endometrial cancer is not dismissed as a diagnosis. ... Brand name: Aleve PM). Abiraterone acetate tablets (250 mg) to treat patients with metastatic castration-resistant prostate cancer.
Men with prostate cancer may survive longer with radical prostatectomy than watchful waiting, especially if they are younger than 65 years of age at diagnosis, a study suggested. ... prostate cancer, and 15.8 percentage points in the risk of metastases
A warning letter to Lab Corporation of America for marketing OvaSure, a test the company says can detect ovarian cancer, without having FDA approval for the test. ... Examine patients prior to therapy to rule out prostate cancer. The most common side
Men with average or low PSA levels had negligible rates of prostate cancer or death by age 85. ... prostate cancer (AUC, 0.90; 95% CI, 0.84 to 0.96; P<0.001).
As the evidence on the utility of prostate-specific antigen screening for prostate cancer continues to be questioned, internists may wonder what to tell their patients about when, how and whether ... Screening can help detect prostate cancer early, but
https://acpinternist.org/weekly/archives/2014/11/04/6.htm. Androgen-deprivation therapy (ADT) for prostate cancer was associated with a 5% absolute excess risk of cardiac-specific mortality at 5 ... Researchers analyzed information on 5,077 men (median
If the device is used during intraoperative radiation therapy for breast cancer, these particles can be mistaken for suspicious calcifications during follow-up X-rays or scans. ... Abiraterone acetate (Zytiga) to treat metastatic, castration-resistant
The primary endpoint was prostate-cancer specific mortality, analyzed according to the intention-to-screen principle. ... Moreover, the results show that in certain circumstances, PSA testing and early diagnosis reduces death from prostate cancer.
It also dissolves easily in a small volume of water. Tbo-filgrastim, a biologic drug to reduce severe neutropenia in patients receiving cancer chemotherapy. ... Enzalutamide (Xtandi) to treat metastatic castration-resistant prostate cancer that has
https://acpinternist.org/weekly/archives/2012/08/07/2.htm. Prostate-specific antigen (PSA) screening reduced the number of men presenting with metastatic prostate cancer, a new study found. ... Prostate-specific antigen (PSA) screening reduced the number